Case 2: 63-Year-Old Female Patient With Metastatic Melanoma on Dual Immunotherapy Developing Treatment-Related Myocarditis

EP: 1.An Overview of the Landscape Surrounding Melanoma

EP: 2.The Role of Biomarker Testing in Melanoma

EP: 3.The Current Landscape Surrounding Adjuvant Therapy in Melanoma

EP: 4.Combination Immunotherapy Strategies for Melanoma in the Adjuvant Setting

EP: 5.Navigating Challenges in Predicting and Mitigating Adverse Events in Adjuvant Immunotherapy

EP: 6.Exploring Immunotherapy Resistance: Impact on Treatment Decisions in Melanoma

EP: 7.Balancing Quality of Life: Adjuvant Therapy Toxicity in Melanoma Adjuvant Immunotherapy

EP: 8.Case 1: Man Aged 55 Years With Stage IIIB Melanoma Developing Immunotherapy-Induced Diabetes

EP: 9.Immunotherapy-Related Diabetes in Melanoma: A Management Perspective

EP: 10.Immunotherapy-Induced Adrenal Insufficiency in Melanoma: Surveillance and Management

Now Viewing

EP: 11.Case 2: 63-Year-Old Female Patient With Metastatic Melanoma on Dual Immunotherapy Developing Treatment-Related Myocarditis

EP: 12.Approaches to Diagnosing and Managing Myocarditis Related to Immunotherapy

EP: 13.Expert Perspectives on Cardiac Baseline and Surveillance Testing in Immunotherapy Recipients

EP: 14.Corticosteroid Treatment Challenges in Patients with Immunotherapy-Related Toxicities

EP: 15.Forward Outlook and Clinical Insights in Melanoma Treatment

This is a video synopsis/summary of an OncLive Insights involving Afreen Shariff, MD, MBBS; Javid Moslehi, MD; and Nikhil Khushalani, MD.

Dr Moslehi discusses immune checkpoint inhibitor (ICI) cardiotoxicity, using a case of a melanoma patient on nivolumab/ipilimumab with chest pain and elevated troponin concerning for myocarditis. He provides an overview of cardiac toxicities with ICIs, noting arrhythmias, pericarditis, vasculitis, and myocarditis emerge as key signals. Myocarditis in particular can be deadly due to arrhythmogenicity despite frequently normal ejection fraction. It often occurs early, at a median of 20 to 25 days on ICIs, and while limited data on risk factors exist, combination immunotherapy clearly elevates risk vs monotherapy. Dr Moslehi concludes that though the exact incidence remains unclear, reported mortality with checkpoint myocarditis remains at 30% to 40%.

Video synopsis is AI-generated and reviewed by OncLive^® editorial staff.